EMPLOYMENT AGREEMENTEmployment Agreement • February 14th, 2022 • Aytu Biopharma, Inc • Pharmaceutical preparations • Colorado
Contract Type FiledFebruary 14th, 2022 Company Industry JurisdictionThis Employment Agreement (the "Agreement"), is effective as of January 17, 2022 (the “Effective Date”), between Aytu BioPharma, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 206, Englewood, CO 80112 USA, hereinafter referred to as the "Company"), and Mark Oki (“Executive").
EMPLOYMENT AGREEMENTEmployment Agreement • April 5th, 2021 • Aytu Biopharma, Inc • Pharmaceutical preparations • Texas
Contract Type FiledApril 5th, 2021 Company Industry JurisdictionThis Employment Agreement (the "Agreement"), is effective as of March 31, 2021 (the “Effective Date”), between Aytu BioPharma, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 206, Englewood, CO 80112 USA, hereinafter referred to as the "Company"), and Richard I. Eisenstadt (“Employee").
EMPLOYMENT AGREEMENTEmployment Agreement • May 10th, 2019 • Neos Therapeutics, Inc. • Pharmaceutical preparations • Pennsylvania
Contract Type FiledMay 10th, 2019 Company Industry JurisdictionThis Employment Agreement (“Agreement”) is made by and between Neos Therapeutics, Inc., a Delaware corporation (the “Company”), and John M. Limongelli (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • June 27th, 2018 • Neos Therapeutics, Inc. • Pharmaceutical preparations • Pennsylvania
Contract Type FiledJune 27th, 2018 Company Industry JurisdictionThis Employment Agreement (“Agreement”) is made by and between Neos Therapeutics, Inc., a Delaware corporation (the “Company”), and Jerry McLaughlin (the “Executive”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • July 13th, 2015 • Neos Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledJuly 13th, 2015 Company Industry JurisdictionThis Amended and Restated Employment Agreement (“Agreement”) is made as of the 10th day of July, 2015 (the “Effective Date”), between Neos Therapeutics, a Delaware corporation (the “Company”), and Vipin K. Garg, Ph.D. (the “Executive”).